Inovio Pharmaceuticals (INO)
Develops DNA medicines and CELLECTRA devices, led by INO-3107 for recurrent respiratory papillomatosis.
$1.29
vs last close0.00 (0.00%)
Something off on this page? Send us feedback.
Next report
Nov 10, 26
in 48 days
EPS estimate
−$0.20
Revenue estimate
$2.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.69−$0.51−$0.61−$0.87$0.06−$0.28−$0.07Pending
Estimate−$0.87−$0.74−$0.63−$0.42−$0.37−$0.35−$0.22−$0.20
Surprise+20.7%+31.1%+3.2%−106.3%+116.2%+20.0%+67.7%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$117.0K$65.3K—————Pending
Estimate$50.0K$10.0K$10.0K$10.0K$333.3K$333.3K$533.3K$2.3M
Surprise+134.0%+553.4%——————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.06 | — | — |
| Sep 2027 | −$0.10 | — | — |
| Jun 2027 | −$0.13 | — | — |
| Mar 2027 | −$0.18 | — | — |
| Dec 2026 | −$0.18 | — | — |
| Nov 2026 | −$0.20 | — | — |
| Aug 2026 | −$0.22 | −$0.07 | +67.7% |
| May 2026 | −$0.35 | −$0.28 | +20.0% |
| Mar 2026 | −$0.37 | $0.06 | +116.2% |
| Nov 2025 | −$0.42 | −$0.87 | −106.3% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.06 | — | — | $27.8M | — | — | — |
| Sep 2027 | −$0.10 | — | — | $20.6M | — | — | — |
| Jun 2027 | −$0.13 | — | — | $14.1M | — | — | — |
| Mar 2027 | −$0.18 | — | — | $6.9M | — | — | — |
| Dec 2026 | −$0.18 | — | — | $666.7K | — | — | — |
| Nov 10, 2026 | −$0.20 | — | — | $2.3M | — | — | — |
| Aug 12, 2026 | −$0.22 | −$0.07 | +67.7% | $533.3K | — | — | +16.9% |
| May 13, 2026 | −$0.35 | −$0.28 | +20.0% | $333.3K | — | — | +1.5% |
| Mar 12, 2026 | −$0.37 | $0.06 | +116.2% | $333.3K | — | — | −1.2% |
| Nov 10, 2025 | −$0.42 | −$0.87 | −106.3% | $10.0K | — | — | −7.0% |
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 18, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 13, 2024 | |||||||
| Mar 6, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 10, 2023 | |||||||
| Mar 1, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 10, 2021 | |||||||
| Mar 1, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 12, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 9, 2018 | |||||||
| Mar 14, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 15, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Mar 14, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 |